Brussels, 13 February 2026 – EuropaBio is pleased to welcome the Association of Biopharmaceutical Manufacturers in Latvia (BRAL) as its newest member.

Founded in 2012, BRAL unites Latvia’s biopharmaceutical sector and works closely with national health authorities to advance policies in personalised medicine, rare diseases, oncology care, and digital health.

As part of its membership, BRAL will contribute national insights and healthcare expertise to support EU-level regulatory development and ensure a predictable and sustainable environment for biopharmaceutical innovation.

In joining EuropaBio, BRAL aims to align Latvia’s policy priorities with European advocacy, strengthen collaboration through the Healthcare and National Associations Councils, and accelerate patient access to innovative therapies across Latvia and the wider region.

Dr. Claire Skentelbery, Director General of EuropaBio, said: “EuropaBio is delighted to increase its representation of Latvia and bring a critical voice into the centre of Europe’s biotechnology future.”

Janis Silins, Member of the Board, Association of Biopharmaceutical Manufacturers in Latvia (BRAL), said: "BRAL is proud to join EuropaBio. This partnership provides an excellent opportunity to ensure that science and healthcare policy go hand-in-hand, accelerating the access to innovative therapies for patients in Latvia and throughout the European health landscape."

For more information, please visit https://bral.lv/en/